Cell and gene therapies (C&GTs) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C&GTs are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).

BioSpace takes a look at the flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites.

Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

CureVac’s Covid-19 vaccine was 48 percent effective in the final analysis of the company’s pivotal mass trial, only marginally better than the 47 percent reported after an initial read-out two weeks earlier.

Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.

In this webinar hear from “both sides of the house” – first from an innovative information technology leader and then a senior scientist who uses the solutions provided by IT. Learn how MOMA Therapeutics’ innovative lead discovery solution can be applied to the needs of biotechnology discovery workflows.

Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.

A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the Covid-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.

Last year challenged biotech and pharma companies to explore what is possible. When several companies can develop COVID-19 vaccines at a record pace, it proves that the industry is capable of massive feats.

CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.